Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02434666 · ClinicalTrials.gov registry record · Phase 2
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
A Phase 2 study of Dementia of the Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT02434666: Completed Phase 2 study of Dementia of the Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
NCT02434666 is a Phase 2 study of Dementia of the Alzheimer's Type that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02434666, a Phase 2 study of Dementia of the Alzheimer's Type, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
Primary Outcome
To evaluate the safety labs and adverse events from baseline, during the study and at the end of the study.
Conditions Studied
Interventions
- DRUG CPC-201
Study Locations (5)
Florida
- Miami Jewish Health Systems - Miami
- Quantum Laboratories, Inc. Memory Disorder Center - Pompano Beach
- Premiere Research Institute Neuroscience - West Palm Beach
Indiana
- IU School of Medicine IU Health Neuroscience Center - Indianapolis
North Carolina
- Giles Cromwell, MD - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 2 |
What the finished NCT02434666 record still lists
NCT02434666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Dementia of the Alzheimer's Type appearing as the primary indexed condition, and to 1 intervention - of which CPC-201 is the first listed.
NCT02434666 lists 5 locations in 3 states (Florida, Indiana, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02434666 about?
NCT02434666 is a clinical study titled "Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07". This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
What is the current status of trial NCT02434666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2015-01-08. Estimated completion is 2016-11-22.
What conditions does trial NCT02434666 study?
This clinical trial studies the following conditions: Dementia of the Alzheimer's Type.
What interventions are being tested in trial NCT02434666?
The interventions under investigation include: CPC-201 (DRUG).
Who is sponsoring clinical trial NCT02434666?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02434666 being conducted?
This trial has 5 study locations across Florida, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02434666's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI